O	0	13	Consolidation
O	14	18	with
B-intervention	19	23	high
I-intervention	23	24	-
I-intervention	24	28	dose
I-intervention	29	40	combination
I-intervention	41	51	alkylating
I-intervention	52	58	agents
O	59	63	with
O	64	68	bone
O	69	75	marrow
O	76	91	transplantation
O	92	105	significantly
O	106	114	improves
O	115	122	disease
O	122	123	-
O	123	127	free
O	128	136	survival
O	137	139	in
O	140	147	hormone
O	147	148	-
O	148	159	insensitive
O	160	170	metastatic
O	171	177	breast
O	178	184	cancer
O	185	187	in
O	188	196	complete
O	197	206	remission
O	207	215	compared
O	216	220	with
O	221	230	intensive
O	231	239	standard
O	239	240	-
O	240	244	dose
O	245	257	chemotherapy
O	258	263	alone
O	263	264	.

O	265	267	We
O	268	277	conducted
O	278	282	this
O	283	288	study
O	289	291	to
O	292	301	determine
O	302	307	event
O	307	308	-
O	308	312	free
O	313	316	and
O	317	324	overall
O	325	333	survival
O	334	339	among
B-eligibility	340	345	women
I-eligibility	346	350	with
I-eligibility	351	358	hormone
I-eligibility	358	359	-
I-eligibility	359	370	insensitive
I-eligibility	371	373	or
I-eligibility	374	381	hormone
I-eligibility	381	382	-
I-eligibility	382	391	resistant
I-eligibility	392	402	metastatic
I-eligibility	403	409	breast
I-eligibility	410	416	cancer
O	417	426	receiving
O	427	440	consolidation
O	441	445	with
O	446	450	high
O	450	451	-
O	451	455	dose
O	456	468	chemotherapy
O	469	470	(
O	470	473	HDC
O	473	474	)
O	475	478	and
O	479	492	hematopoietic
O	493	500	support
O	501	507	versus
O	508	510	no
O	511	518	further
O	519	531	chemotherapy
O	532	537	after
O	538	547	intensive
O	548	557	induction
O	558	570	chemotherapy
O	570	571	.

O	572	580	Eligible
O	581	589	patients
O	590	598	received
O	599	608	induction
O	609	620	doxorubicin
O	620	621	,
O	622	623	5
O	623	624	-
O	624	636	fluorouracil
O	636	637	,
O	638	641	and
O	642	654	methotrexate
O	655	656	(
O	656	659	AFM
O	659	660	)
O	661	664	for
O	665	666	2
O	667	669	to
O	670	671	4
O	672	678	cycles
O	678	679	.

O	680	685	Women
O	686	688	in
O	689	697	complete
O	698	707	remission
O	708	712	were
O	713	723	randomized
O	724	726	to
O	727	736	immediate
O	737	740	HDC
O	741	745	with
O	746	762	cyclophosphamide
O	762	763	,
O	764	773	cisplatin
O	773	774	,
O	775	778	and
O	779	789	carmustine
O	790	798	followed
O	799	801	by
O	802	812	autologous
O	813	826	hematopoietic
O	827	834	support
O	835	837	or
O	838	840	to
O	841	843	no
O	844	851	further
O	852	859	therapy
O	859	860	.

O	861	869	Patients
O	870	872	on
O	873	876	the
B-control	877	888	observation
I-control	889	892	arm
O	893	895	of
O	896	903	therapy
O	904	908	were
O	909	916	offered
O	917	924	salvage
O	925	928	HDC
O	929	931	at
O	932	935	the
O	936	940	time
O	941	943	of
O	944	951	relapse
O	951	952	.

O	953	960	Partial
O	961	971	responders
O	972	974	to
O	975	978	AFM
O	979	983	were
O	984	991	offered
O	992	1001	immediate
O	1002	1005	HDC
O	1005	1006	.

O	1007	1008	A
O	1009	1014	total
O	1015	1017	of
B-total-participants	1018	1021	425
O	1022	1030	patients
O	1031	1035	were
O	1036	1044	enrolled
O	1045	1049	onto
O	1050	1053	the
O	1054	1059	study
O	1059	1060	.

O	1061	1064	The
B-outcome	1065	1071	median
I-outcome	1072	1077	event
I-outcome	1077	1078	-
I-outcome	1078	1082	free
I-outcome	1083	1091	survival
O	1092	1095	for
O	1096	1101	women
O	1102	1112	randomized
O	1113	1115	to
O	1116	1125	induction
O	1126	1133	therapy
O	1134	1139	alone
O	1140	1143	was
B-cv-cont-median	1144	1145	3
I-cv-cont-median	1145	1146	.
I-cv-cont-median	1146	1147	8
I-cv-cont-median	1148	1154	months
O	1154	1155	,
O	1156	1164	compared
O	1165	1169	with
B-iv-cont-median	1170	1171	9
I-iv-cont-median	1171	1172	.
I-iv-cont-median	1172	1173	7
I-iv-cont-median	1174	1180	months
O	1181	1184	for
O	1185	1190	women
O	1191	1194	who
O	1195	1204	completed
O	1205	1208	HDC
O	1209	1210	(
O	1210	1211	P
O	1212	1213	<
O	1214	1215	.
O	1215	1218	006
O	1218	1219	)
O	1219	1220	.

O	1221	1223	Of
O	1224	1227	the
O	1228	1236	patients
O	1237	1247	randomized
O	1248	1250	to
O	1251	1262	observation
O	1262	1263	,
B-cv-bin-abs	1264	1265	5
O	1266	1267	(
B-cv-bin-percent	1267	1269	10
I-cv-bin-percent	1269	1270	%
O	1270	1271	)
O	1272	1274	of
B-control-participants	1275	1277	51
O	1278	1284	remain
B-outcome	1285	1290	event
I-outcome	1291	1295	free
O	1295	1296	,
O	1297	1305	compared
O	1306	1310	with
B-iv-bin-abs	1311	1313	13
O	1314	1315	(
B-iv-bin-percent	1315	1317	26
I-iv-bin-percent	1317	1318	%
O	1318	1319	)
O	1320	1322	of
B-intervention-participants	1323	1325	49
O	1326	1334	patients
O	1335	1338	who
O	1339	1348	underwent
O	1349	1358	immediate
O	1359	1362	HDC
O	1363	1364	(
O	1364	1365	P
O	1366	1367	=
O	1368	1369	.
O	1369	1371	03
O	1371	1372	)
O	1372	1373	.

O	1374	1376	Of
O	1377	1382	women
O	1383	1392	converted
O	1393	1395	to
O	1396	1397	a
O	1398	1406	complete
O	1407	1415	response
O	1416	1418	by
O	1419	1426	salvage
O	1427	1430	HDC
O	1431	1436	after
O	1437	1438	a
O	1439	1446	partial
O	1447	1455	response
O	1456	1458	to
O	1459	1462	AFM
O	1462	1463	,
B-outcome	1464	1471	overall
I-outcome	1472	1480	survival
O	1481	1484	was
O	1485	1492	similar
O	1493	1495	to
O	1496	1500	that
O	1501	1503	in
O	1504	1509	women
O	1510	1520	randomized
O	1521	1523	to
O	1524	1533	immediate
O	1534	1537	HDC
O	1537	1538	.

O	1539	1545	Follow
O	1545	1546	-
O	1546	1548	up
O	1549	1551	is
O	1552	1555	now
O	1556	1558	in
O	1559	1565	excess
O	1566	1568	of
O	1569	1570	5
O	1571	1576	years
O	1576	1577	.

O	1578	1581	The
B-outcome	1582	1583	5
I-outcome	1583	1584	-
I-outcome	1584	1588	year
I-outcome	1589	1594	event
I-outcome	1594	1595	-
I-outcome	1595	1599	free
I-outcome	1600	1608	survival
O	1609	1611	is
O	1612	1614	15
O	1614	1615	%
O	1616	1617	(
O	1617	1619	95
O	1619	1620	%
O	1621	1631	confidence
O	1632	1640	interval
O	1640	1641	,
O	1642	1644	12
O	1644	1645	%
O	1645	1646	-
O	1646	1648	18
O	1648	1649	%
O	1649	1650	)
O	1650	1651	,
O	1652	1655	and
O	1656	1659	the
B-outcome	1660	1661	5
I-outcome	1661	1662	-
I-outcome	1662	1666	year
I-outcome	1667	1674	overall
I-outcome	1675	1683	survival
O	1684	1686	is
O	1687	1689	20
O	1689	1690	%
O	1691	1692	(
O	1692	1694	95
O	1694	1695	%
O	1696	1706	confidence
O	1707	1715	interval
O	1715	1716	,
O	1717	1719	17
O	1719	1720	%
O	1720	1721	-
O	1721	1723	25
O	1723	1724	%
O	1724	1725	)
O	1725	1726	.

O	1727	1736	Immediate
O	1737	1740	HDC
O	1741	1746	after
O	1747	1748	a
O	1749	1757	complete
O	1758	1766	response
O	1767	1769	to
O	1770	1773	AFM
O	1774	1782	produced
O	1783	1787	some
O	1788	1795	durable
O	1796	1800	long
O	1800	1801	-
O	1801	1805	term
O	1806	1815	responses
O	1816	1818	in
O	1819	1826	hormone
O	1826	1827	-
O	1827	1838	insensitive
O	1838	1839	/
O	1839	1840	-
O	1840	1849	resistant
O	1850	1860	metastatic
O	1861	1867	breast
O	1868	1874	cancer
O	1874	1875	.

O	1876	1883	Salvage
O	1884	1887	HDC
O	1888	1897	converted
O	1898	1900	30
O	1900	1901	%
O	1902	1904	of
O	1905	1912	partial
O	1913	1923	responders
O	1924	1926	to
O	1927	1935	complete
O	1936	1946	responders
O	1947	1951	with
O	1952	1959	similar
O	1960	1969	survivals
O	1969	1970	.

O	1971	1974	The
O	1975	1983	addition
O	1984	1986	of
O	1987	1992	novel
O	1993	2001	targeted
O	2002	2011	therapies
O	2012	2014	to
O	2015	2024	intensive
O	2024	2025	-
O	2025	2029	dose
O	2030	2042	chemotherapy
O	2043	2051	regimens
O	2052	2055	may
O	2056	2063	further
O	2064	2071	improve
O	2072	2080	survival
O	2081	2083	in
O	2084	2094	metastatic
O	2095	2101	breast
O	2102	2108	cancer
O	2108	2109	.
